Connect with us

Medical Devices

Analytica Announces Expansion of Enhanced Infusion System into Middle East

Avatar

Published

on

Analytica Limited (ASX:ALT), the Australian developer of the Enhanced Infusion System (EIS) and PeriCoach® pelvic floor exercise system for the treatment of stress urinary incontinence, has entered into an agreement with Marwa’s Office for Export & Import Medical Supplies (Marwa) to distribute, market and sell the EIS to hospital systems in Egypt, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Saudi Arabia and United Arab Emirates.

The EIS technology was developed by Analytica under the project names AutoStart and AutoFlush and has been sold in Australia with the trade name FirstFlow™, under limited license. EIS combines the AutoStart and AutoFlush patented technologies into a simple and inexpensive solution.

The patented float system automatically restarts IV fluid flow following medication delivery, thereby saving healthcare workers’ time, reducing hospital costs and preventing the adverse events associated with air embolism and failure of Peripheral Intravenous Catheters (PIVC). The EIS reacts immediately, silently and without intervention or programming. It can be retrofitted to any existing infusion system design and can work in harmony with and improve the capability of any infusion pump or ‘bag’ infusion system, regardless of sophistication.

Use of the EIS uniquely allows a completely closed infusion system, with integrity achieved by reducing the interactions believed to cause mechanical and vascular complications as well as good flushing and/or patency practice.

The EIS has an Australian TGA ARTG registration and USFDA 510(k) clearance. It is fully compliant with ISO 8536 infusion system and other relevant standards.

The EIS can markedly reduce legal risks by addressing multiple factors that can impact patients, clinicians and hospitals, including:

  • Air Embolism – The EIS has a large and heavy float valve ensuring complete, long-term seal. The unique float maintains a seal even at extreme angles (up to 60 degrees from horizontal), making the device usable in ambulances, retrieval and military situations and reducing the risk of mortality and morbidity associated with air embolism.
  • Open/Closed Delivery System – The needle-free access port is the only entry point, with only one syringe necessary per medication event. Using the existing 1L IV bag means replacement is less frequent than 100mL pre-mix bags, saving time and money and reducing the risk of contamination and infection.
  • Syringe Flush – This feature eliminates the requirement to introduce an additional flushing syringe and bolus. Flushing prevents interactions between incompatible fluids/medications, thus reducing the risk of cross contamination and strengthening infection control.
  • Catheter Flush – This feature reduces the risk of PIVC failure with the automatic, immediate restart of IV flow after medication delivery, which allows continuous maintenance flow to the flush line and catheter. This also maintains catheter patency by preventing internal luminal occlusion.
  • Medication Dilution – The Interrupted Therapy feature allows the introduction of medication through EIS to accurately measure IV fluid mix rather than 3-way valve and bags.
  • Infection Risk – Observational studies demonstrate high incidence of non-conformance to hand washing and flushing protocol. EIS limits access and infection opportunity.
  • Flushing pressure – Bolus flush of catheter may vary based on syringe size and pressure. The proprietary float design ensures constant flushing pressure, reducing the risk of PIVC failure.

Given the health and legal risk-reduction features of the EIS, the home-based hospital care market represents a growth opportunity globally. The EIS is compact, rugged and does not require a pump or energy source, which makes it suitable for retrieval, military and third world needs without compromising risk.

To view a video about the operation and features of the EIS, please click here.

Marwa’s Principal has extensive experience with the Egyptian health system, as a consultant and undersecretary of health for the Egyptian Health Insurance Organization Clinics (HIO) as well as leadership positions in the Egyptian Ministry of Health.

“Marwa has presented a compelling opportunity with experienced professionals to take Analytica’s Enhanced Infusion System (EIS) into a large and growing market in the Middle East,” said Dr. Michael Monsour, Chairman of Analytica Ltd. “We look forward to working with Marwa to expand the usage of our unique EIS technology.”

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/analytica-announces-expansion-of-enhanced-infusion-system-into-middle-east/

Medical Devices

What is a Person Responsible for Regulatory Compliance

Avatar

Published

on

Continue Reading

Medical Devices

Becton Dickinson prepares to say goodbye to its $1B diabetes care business

Avatar

Published

on

diabetes, insulin

Becton Dickinson, a company that was among the first to sell glass syringes and then grew to become a global leader in insulin delivery products, is spinning off diabetes care into a separate business, a move it says will better position each entity to grow.

The new, yet-to-be-named diabetes company will have corporate offices in New Jersey and Massachusetts. It will be led by Dev Kurdikar, who is currently worldwide president of BD Diabetes Care. He’ll oversee a business that makes about 8 billion devices a year serving an estimated 30 million patients worldwide, according to an investor presentation. The diabetes business generates nearly $1.1 billion in annual sales, more than half of which is from the U.S. When the spinoff is complete, the new company will be publicly traded.

As currently structured, Franklin Lakes, New Jersey-based BD divides its operations into three business segments: BD Medical, BD Life Sciences, and BD Interventional. The largest of the three is the medical segment, which generated about $8.7 billion in revenue in fiscal 2020.

Diabetes care, which includes syringes, pen needles, and products for injecting insulin and other drugs, is part of the medical segment. Sales for diabetes care have held steady at around the $1 billion mark for the past three fiscal years, according to BD’s 2020 annual report.

The life sciences segment, which covers diagnostic products including Covid-19 tests, accounted for $4.7 billion in revenue in the 2020 fiscal year. The interventional segment, which includes surgical products, generated $3.7 billion in revenue. Much of what comprises the interventional segment came to BD via its $24 billion acquisition of C.R. Bard in 2017.

While the new company will hone its focus on diabetes products, the remaining company is pursuing the “BD 2025” growth strategy, which includes R&D investment and tuck-in acquisitions, the investor presentation shows. Those moves are being made in three areas core areas. The first is the application of smart devices, robotics, analytics and artificial intelligence to healthcare processes. Next are technologies for care settings, such as products that control drug storage and prescription filling, as well Covid-19 diagnostic testing in the home. Last are products that improve diagnosis or treatment of chronic diseases.

In a prepared statement, Tom Polen, BD’s CEO and president, said that the spinoff of diabetes care is part of the company’s active portfolio management and fits within the BD 2025 strategy.

“The spinoff will allow BD to strengthen its growth profile, enables a greater investment focus on our other core businesses and high-growth opportunities, and makes a greater impact for our customers and patients,” he said.

The spinoff will happen as a distribution of stock in the new company to BD shareholders. BD said it expects this transaction will be tax free for U.S. shareholders. The deal is expected to be completed
in the first half of 2022.

Photo: Kerem Yucel/AFP, via Getty Images

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://medcitynews.com/2021/05/becton-dickinson-prepares-to-say-goodbye-to-its-1b-diabetes-care-business/

Continue Reading

Medical Devices

Northwell Health Sends Relief to India as Overwhelming Coronavirus Cases Mount

Avatar

Published

on

Northwell Health is readying to send desperately needed supplies, equipment and funds as the country is in the throes of a national health care crisis.

After recently topping 20 million known cases of coronavirus, the resources and finances necessary to respond are becoming scarce. Essential equipment like N95 respirators, personal protective equipment (PPE) and even oxygen is at critical lows – a dangerous combination that is overwhelming India’s public and private health systems and threatening the well-being of over 1.3 billion people.

In response to this need, Northwell Health is providing 1 million KN 95 respirators, 35 ventilators and, in conjunction with the American Association of Physicians of Indian Origin (AAPI), 1,000 desperately needed oxygen concentrators to the hardest hit areas of the country.

These industrial-grade O2 concentrators will play a vital role in this effort, as these machines can be deployed almost anywhere and essentially pull oxygen out of thin air to be used in treating patients. Similar units were used in field hospitals across the United States when dedicated air/gas systems weren’t possible, making them ideal for this mission.

Northwell has also established a fund to support Northwell’s Center for Global Health, which will direct all financial donations received this month to the AAPI who will leverage their local partner network to distribute the funds to directly and exclusively support COVID-19 relief measures.

All of these efforts are being spearheaded by Northwell’s Center for Global Health (CGH). Established in 2019, CGH partners with Northwell department leadership to develop new programs in its core sites – Ecuador, Guyana, and India – and supports existing programs in their affiliate sites in the Dominican Republic, Kenya, and Uganda. Providers engage in global health activities to help positively impact the health of communities abroad while equipping our providers with skills that inform practice and support patient-centered care globally and locally.

“We’ve been working with our partners and vendors [in the United States] to get supplies donated, to get shipping and cargo and air freight donated, to get the supplies as quickly as possible,” said Eric Cioe-Peña, MD, who serves as the director for the Center for Global Health.

Dr. Cioe-Peña stressed the important role of Northwell Health’s supply chain and logistical support. “We also need to make sure that when we’re sending these supplies, we’re placing them strategically in the country.” He added that due to the size and scale of this crisis, India’s overall landmass and added travel restrictions, many factors come in to play to get these supplies to the hospitals and patients that need them the most.

This is another area AAPI comes into play.

Dr. Shashi Shah, chief of Urology at Northwell’s Long Island Jewish Medical Center and member of AAPI, which represents over 80,000 physicians of Indian origin, has been coordinating between the two organizations to help streamline the process.

“Through AAPI’s network of physicians and our relationships in India, particularly in the health systems, we can align with the right people who can help us make the most informed decisions and get these supplies – and just as important – the funds they need to address this crisis,” he said.

Northwell’s supply run is currently underway as an initial shipment of masks and PPE left JFK International Airport early Tuesday, May 4. They expect the full sum of equipment in country by the end of the week.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/northwell-health-relief-to-india/

Continue Reading

Medical Devices

Aerobiotix Raises $25M Growth Equity Financing Led by Global Healthcare Investment Firm Vivo Capital

Avatar

Published

on

Aerobiotix, a rapidly growing global medical company has raised a $25 million of growth equity financing.

The round was led by Vivo Capital with participation by Asahi Kasei Ventures. The new funding will be used to accelerate sales, marketing, and new product development. The Company’s infection control products have been used to support thousands of procedures across multiple surgical specialty disciplines and in over 175 hospitals and multiple long-term care facilities.

Aerobiotix has developed a novel suite of FDA 510(k) cleared hospital-based air decontamination products and its devices are supported by multiple peer-reviewed research studies. Aerobiotix devices, such as the operating-room based ILLUVIA® system, are used by leading healthcare centers to reduce bacterial and viral contamination, including SARS-CoV-2 and other emerging pathogens. Aerobiotix products provide mechanical and ultraviolet filtration to remove airborne threats with high efficiency to protect healthcare staff and visitors, and to reduce surgery-related infection risk for patients.

“Healthcare doesn’t stop at the patient, it encompasses an environment which is as important to outcomes as direct interventions. As we transition to a post-pandemic world, we are reminded of the long-term need for better environmental stewardship in healthcare and other critical settings. Aerobiotix is on the vanguard of this approach with direct decontamination, real-time air quality monitoring and internet of medical things connectivity,” states Dr. David Kirschman, founder and CEO of Aerobiotix.

Joseph Siletto, Managing Director at Vivo Capital noted, “Infection control has been an increasingly important area of focus for healthcare institutions. In particular, finding ways to reduce surgical site infections is a key priority since SSIs are extremely costly to patients, caregivers and healthcare systems. The Aerobiotix line of products provide healthcare institutions an effective, clinically proven way to improve safety and improve quality of care.”

“We have been very impressed by the Aerobiotix team and their ability to rapidly rollout a suite of innovative infection control products. The strong commercial traction Aerobiotix has achieved with limited outside capital attests to the value of the Aerobiotix solution. We are excited to partner with Aerobiotix to accelerate growth both domestically and internationally,” added Nathan Dau, Executive Director at Vivo Capital.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://infomeddnews.com/aerobiotix-raises-25-million-growth-equity-financing/

Continue Reading
Aviation4 days ago

American Airlines Passenger Arrested After Alleged Crew Attack

Blockchain4 days ago

The Reason for Ethereum’s Recent Rally to ATH According to Changpeng Zhao

Blockchain2 days ago

Chiliz Price Prediction 2021-2025: $1.76 By the End of 2025

Blockchain3 days ago

Mining Bitcoin: How to Mine Bitcoin

Blockchain3 days ago

Mining Bitcoin: How to Mine Bitcoin

Fintech5 days ago

Talking Fintech: Customer Experience and the Productivity Revolution

Blockchain5 days ago

Bitcoin Gains Bullish Momentum, Signals Another Major Rally

PR Newswire3 days ago

Teamsters Lead Historic Defeat of CEO Pay at Marathon Petroleum

Blockchain5 days ago

Ethereum Market Capital Overtakes Bank of America

Blockchain3 days ago

Mining Bitcoin: How to Mine Bitcoin

Startups5 days ago

Equity Monday: TechCrunch goes Yahoo while welding robots raise $56M

Cyber Security5 days ago

Alaska Court System Temporarily Disconnected the Internet After a Cybersecurity Threat

AR/VR1 day ago

Apple is giving a laser company that builds some of its AR tech $410 million

Esports3 days ago

TFT 11.9 B-patch nerfs Mordekaiser and LeBlanc

Blockchain3 days ago

Amid XRP lawsuit, Ripple appoints former US Treasurer to its board, and names new CFO

Crowdfunding5 days ago

Cryptocurrency ATM Network Bitcoin Depot Launches More Than 350 New ATMs Across the U.S.

Cyber Security5 days ago

Incident Detection and Response Basics Greatly Matter

AR/VR5 days ago

Holoride Secures $12M Funding to Create Immersive in-car VR Experiences

Blockchain3 days ago

Galaxy Digital Set To Buy BitGo for $1.2 Billion

AI5 days ago

Education lender Climb Credit taps Zest AI for credit underwriting

Trending